BriaCell Reports Extended Progression-Free Survival To 9.1 Months In ADC Resistant Metastatic Breast Cancer Patient; Top Responder Continues Bria-IMT Treatment In Phase 2 Study
Portfolio Pulse from Benzinga Newsdesk
BriaCell reports extended progression-free survival to 9.1 months in ADC resistant metastatic breast cancer patients. A top responder continues Bria-IMT treatment in a Phase 2 study, showing significant reduction of a 'eye-bulging' tumor after failing 8 prior regimens.
July 18, 2024 | 11:58 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BriaCell Therapeutics has reported extended progression-free survival to 9.1 months in ADC resistant metastatic breast cancer patients. A top responder continues Bria-IMT treatment in a Phase 2 study, showing significant reduction of a 'eye-bulging' tumor after failing 8 prior regimens.
The news highlights significant clinical progress for BriaCell's Bria-IMT treatment, which could positively impact investor sentiment and the stock price. The extended progression-free survival and continued treatment of a top responder indicate promising efficacy, which is crucial for biotech companies in clinical stages.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100